Laboratory monitoring of high-dose factor VIIa therapy

被引：14

作者：

Hoffman, M ^{[1
]}

机构：

[1] Duke Univ, Med Ctr, Durham, NC 27705 USA

来源：

ANNALS OF INTERNAL MEDICINE | 2003年 / 139卷 / 09期

关键词：

D O I：

10.7326/0003-4819-139-9-200311040-00020

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：791 / 791

页数：1

共 5 条

[1]

Deveras RAE, 2002, ANN INTERN MED, V137, P884, DOI 10.7326/0003-4819-137-11-200212030-00009

[2] On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: focus on prothrombin activation [J].

Gerotziafas, GT ;

Zervas, K ;

Arzoglou, P ;

Karavaggeli, E ;

Parashou, S ;

Van Dreden, P ;

Christakis, J ;

Samama, MM .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (03) :705-708

[3] The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis [J].

Hoffman, M ;

Monroe, DM .

SEMINARS IN HEMATOLOGY, 2001, 38 (04) :6-9

[4] Platelet activity of high-dose factor VIIa is independent of tissue factor [J].

Monroe, DM ;

Hoffman, M ;

Oliver, JA ;

Roberts, HR .

BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (03) :542-547

[5] MECHANISM BY WHICH RECOMBINANT FACTOR-VIIA SHORTENS THE APTT - ACTIVATION OF FACTOR-X IN THE ABSENCE OF TISSUE FACTOR [J].

TELGT, DSC ;

MACIK, BG ;

MCCORD, DM ;

MONROE, DM ;

ROBERTS, HR .

THROMBOSIS RESEARCH, 1989, 56 (05) :603-609

← 1 →